Compare Sana Biotechnology Inc (SANA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs J M Smucker Co — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while J M Smucker Co trades at $117.46 (market cap $12.54B). The key difference: J M Smucker Co is far larger — about 11.1× Sana Biotechnology Inc's market cap, and J M Smucker Co pays a 3.82% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SJM | |
|---|---|---|
Market Cap | $1.13B | $12.54B |
Sector | Health | Consumer Staples |
52-Week High | $5.92 | $126.35 |
52-Week Low | $2.68 | $89.53 |
Enterprise Value | $1.05B | $19.57B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
SJM trades at $118.84, up 0.65% today, with a bullish technical signal and support near $117. The company reported revenue of $8.73B in 2025 but a net loss of -$1.23B, though recent quarters show earnings beats. Analyst consensus is a Buy with a $125.11 price target, and the dividend was recently increased to $1.12 per share, marking 25 consecutive years of growth.
Outlook is mixed: strong cash flow and dividend growth support income investors, but negative margins and high debt pose risks. Upside depends on cost controls and Uncrustables growth offsetting sales declines. The stock offers value at a P/E of 22.05 but faces execution challenges in a competitive consumer staples market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
